Axsome settles patent litigation with Teva
Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The ...
Shares of Axsome Therapeutics ( AXSM 4.36%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...
Mizuho raised the firm’s price target on Axsome Therapeutics (AXSM) to $195 from $137 and keeps an Outperform rating on the shares following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results